Abstract
Objective To evaluate the efficacy and safety of bepotastine besilate in the treatment of chronic urticaria.Methods A randomized,double-blind,parallel-controlled clinical study was conducted in 5 centers.Patients were randomly assigned to 2 groups to be treated with bepotastine besilate 20 mg or loratadine 10 mg once a day,respectively,for 4 weeks.Visits were scheduled before and after 1,2 and 4 weeks of treatment.Itching degree,number of wheals and diameter of the largest wheal were recorded for efficacy evaluation.Results Totally,240 patients were enrolled and 227 patients completed the study.The response rate was 74.6％ and 77.9％ respectively in bepotastine besilate- and loratadine-treated patients,respectively(P ＞0.05).No significant difference was observed in the incidence of adverse reactions between bepotastine besilate- and loratadine-treated patients (12.8％ vs.17.9％,P ＞ 0.05).The main side effects were mild to moderate drowsiness,dry mouth,dizziness.Conclusion Bepotastine besilate is effective and safe for the treatment of chronic urticaria,with an efficacy and safety profile similar to that of loratadine. Key words: Urticaria; Bepotastine besilate; Loratadine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
